Investing Profile

Elena Viboch

InvestorVC
Partner at General Catalyst
generalcatalyst.comSan Francisco Bay Area
Photo of Elena Viboch, Partner at General Catalyst
Your Intro Paths to Elena Viboch

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →

Elena Viboch's investing connections

Picture
Picture

2 Investors

Connected to Saar Gur (CRV), Lisa Marrone (August Capital).

Find Elena Viboch on

cb
Current Investing Position
General Catalyst Partner
Investment Range
$500K - $2.0M
Sweet Spot
$500K
Investments On Record
14
Current Fund Size
$1.1B

Elena Viboch is on these Sector & Stage Rankings

Elena Viboch's Investments On Record (12)

CompanyStageDateRound SizeTotal Raised
Chai Discovery
Series BDec 2025$130M
$230M
Co-investors: Hemant Taneja (General Catalyst), Fred Ehrsam (Paradigm), Greg Yap (Menlo Ventures), Lachy Groom (LGF), Nitesh Banta (Stellar Capital)
Paradigm
Series BDec 2025$78M
Series AJan 2023$200M
$320M
Co-investors: Hemant Taneja (General Catalyst), Ramnik Arora (FTX Ventures), Niko Bonatsos (General Catalyst), Bilal Zuberi (Lux Capital), Stephen Knight (F-Prime Capital Partners), Brett Cook (F-Prime Capital Partners), Alaa Halawa (Mubadala), Jay Markowitz (ARCH Venture Partners), Robert Nelsen (ARCH Venture Partners), Jared Friedman (Y Combinator), Justin Kao (DFJ Growth), Scott Belsky, Arash Ferdowsi, Eoghan McCabe, Balaji Srinivasan, Karim Atiyeh
Maxion Therapeutics
Series AMar 2025$75M
$91M
Co-investors: Lucy Edwardes-Jones (Business Growth Fund)
Medeloop
Series ANov 2024$16M
SeedSep 2023$8M
$24M
Co-investors: Sara Thomas Deshpande (Maven Ventures), Magaly Charbonneau (iNovia Capital)
Alpha-9 Oncology
Series COct 2024$180M
$250M
Co-investors: Patrick Heron (Frazier Healthcare Partners), Melissa McCracken (Nextech Invest), Cory Freedland (Samsara BioCapital)
CTRL Therapeutics
SeedApr 2023$10M
$10M
Faro Health
Series AFeb 2023$20M
$35M
Co-investors: Andy Harrison (Section 32)
ArriVent Biopharma
Series BDec 2022$160M
$160M
Co-investors: Carl Gordon (OrbiMed), James Healy (Sofinnova Investments)